Cargando…

Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke

BACKGROUND: Nowadays, acute intracerebral hemorrhage stroke (AICH) still causes higher mortality. Liangxue Tongyu Formula (LXTYF), originating from a traditional Chinese medicine (TCM) prescription, is widely used as auxiliary treatment for AICH. OBJECTIVE: To dig into the multicomponent, multitarge...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yang, Dong, Ju, Yang, Dongqing, Qian, Qin, Wang, Pengcheng, Yang, Xiaojuan, Li, Wei, Li, Guochun, Shen, Xu, Wang, Fushun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936909/
https://www.ncbi.nlm.nih.gov/pubmed/33727915
http://dx.doi.org/10.1155/2021/8874296
_version_ 1783661286367690752
author Chen, Yang
Dong, Ju
Yang, Dongqing
Qian, Qin
Wang, Pengcheng
Yang, Xiaojuan
Li, Wei
Li, Guochun
Shen, Xu
Wang, Fushun
author_facet Chen, Yang
Dong, Ju
Yang, Dongqing
Qian, Qin
Wang, Pengcheng
Yang, Xiaojuan
Li, Wei
Li, Guochun
Shen, Xu
Wang, Fushun
author_sort Chen, Yang
collection PubMed
description BACKGROUND: Nowadays, acute intracerebral hemorrhage stroke (AICH) still causes higher mortality. Liangxue Tongyu Formula (LXTYF), originating from a traditional Chinese medicine (TCM) prescription, is widely used as auxiliary treatment for AICH. OBJECTIVE: To dig into the multicomponent, multitarget, and multipathway mechanism of LXTYF on treating AICH via network pharmacology and RNA-seq. METHODS: Network pharmacology analysis was used by ingredient collection, target exploration and prediction, network construction, and Gene Ontology (GO) and KEGG analysis, with the Cytoscape software and ClusterProfiler package in R. The RNA-seq data of the AICH-rats were analyzed for differential expression and functional enrichments. Herb-Compound-Target-Pathway (H-C-T-P) network was shown to clarify the mechanism of LXTYF for AICH. RESULTS: 76 active ingredients (quercetin, Alanine, kaempferol, etc.) of LXTYF and 376 putative targets to alleviate AICH (PTGS2, PTGS1, ESR1, etc.) were successfully identified. The protein-protein interaction (PPI) network indicated the important role of STAT3. The functional enrichment of GO and KEGG pathway showed that LXTYF is most likely to influence MAPK and PI3K-Akt signaling pathways for AICH treatment. From the RNA-seq of AICH-rats, 583 differential mRNAs were identified and 14 of them were consistent with the putative targets of LXTYF for AICH treatment. The KEGG pathway enrichment also implied that the MAPK signaling pathway was the most correlated one among all the related signaling pathways. Many important targets with expression changes of LXTYF for AICH treatment and their related pathways are great markers of antioxidation, anti-inflammatory, antiapoptosis, and lowering blood pressure, which indicated that LXTYF may play mutiroles in the mechanisms for AICH treatment. CONCLUSION: The LXTYF attenuates AICH partially by antioxidation, anti-inflammatory, and antiapoptosis and lowers blood pressure roles through regulating the targets involved MAPK, calcium, apoptosis, and TNF signaling pathway, which provide notable clues for further experimental validation.
format Online
Article
Text
id pubmed-7936909
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-79369092021-03-15 Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke Chen, Yang Dong, Ju Yang, Dongqing Qian, Qin Wang, Pengcheng Yang, Xiaojuan Li, Wei Li, Guochun Shen, Xu Wang, Fushun Neural Plast Research Article BACKGROUND: Nowadays, acute intracerebral hemorrhage stroke (AICH) still causes higher mortality. Liangxue Tongyu Formula (LXTYF), originating from a traditional Chinese medicine (TCM) prescription, is widely used as auxiliary treatment for AICH. OBJECTIVE: To dig into the multicomponent, multitarget, and multipathway mechanism of LXTYF on treating AICH via network pharmacology and RNA-seq. METHODS: Network pharmacology analysis was used by ingredient collection, target exploration and prediction, network construction, and Gene Ontology (GO) and KEGG analysis, with the Cytoscape software and ClusterProfiler package in R. The RNA-seq data of the AICH-rats were analyzed for differential expression and functional enrichments. Herb-Compound-Target-Pathway (H-C-T-P) network was shown to clarify the mechanism of LXTYF for AICH. RESULTS: 76 active ingredients (quercetin, Alanine, kaempferol, etc.) of LXTYF and 376 putative targets to alleviate AICH (PTGS2, PTGS1, ESR1, etc.) were successfully identified. The protein-protein interaction (PPI) network indicated the important role of STAT3. The functional enrichment of GO and KEGG pathway showed that LXTYF is most likely to influence MAPK and PI3K-Akt signaling pathways for AICH treatment. From the RNA-seq of AICH-rats, 583 differential mRNAs were identified and 14 of them were consistent with the putative targets of LXTYF for AICH treatment. The KEGG pathway enrichment also implied that the MAPK signaling pathway was the most correlated one among all the related signaling pathways. Many important targets with expression changes of LXTYF for AICH treatment and their related pathways are great markers of antioxidation, anti-inflammatory, antiapoptosis, and lowering blood pressure, which indicated that LXTYF may play mutiroles in the mechanisms for AICH treatment. CONCLUSION: The LXTYF attenuates AICH partially by antioxidation, anti-inflammatory, and antiapoptosis and lowers blood pressure roles through regulating the targets involved MAPK, calcium, apoptosis, and TNF signaling pathway, which provide notable clues for further experimental validation. Hindawi 2021-02-26 /pmc/articles/PMC7936909/ /pubmed/33727915 http://dx.doi.org/10.1155/2021/8874296 Text en Copyright © 2021 Yang Chen et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chen, Yang
Dong, Ju
Yang, Dongqing
Qian, Qin
Wang, Pengcheng
Yang, Xiaojuan
Li, Wei
Li, Guochun
Shen, Xu
Wang, Fushun
Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
title Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
title_full Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
title_fullStr Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
title_full_unstemmed Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
title_short Synergistic Network Pharmacology for Traditional Chinese Medicine Liangxue Tongyu Formula in Acute Intracerebral Hemorrhagic Stroke
title_sort synergistic network pharmacology for traditional chinese medicine liangxue tongyu formula in acute intracerebral hemorrhagic stroke
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936909/
https://www.ncbi.nlm.nih.gov/pubmed/33727915
http://dx.doi.org/10.1155/2021/8874296
work_keys_str_mv AT chenyang synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT dongju synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT yangdongqing synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT qianqin synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT wangpengcheng synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT yangxiaojuan synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT liwei synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT liguochun synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT shenxu synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke
AT wangfushun synergisticnetworkpharmacologyfortraditionalchinesemedicineliangxuetongyuformulainacuteintracerebralhemorrhagicstroke